- Additional data from the KEYNOTE-859 study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancerWyrwicz, L.; Oh, D.; Weber, P.; Bai, Y.; Ryu, M.; Lee, J.; Rivera, F.; Alves, G. Vasconcelos; Garrido, M.; Shiu, K.; Fernandez, M. Gonzalez; Li, J.; Lowery, M.; Cil, T.; Cruz, F.; Qin, S.; Yin, L.; Bordia, S.; Bhagia, P.; Rha, S.
- Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 studyRha, S. Y.*; Wyrwicz, L. S.; Weber, P. E. Y.; Bai, Y.; Ryu, M. H.; Lee, J.; Rivera, F.; Alves, G. V.; Garrido, M.; Shiu, K. -k.; Fernandez, M. Gonzalez; Li, J.; Lowery, M.; Cil, T.; Cruz, F. J. S. M.; Qin, S.; Yin, L.; Bordia, S.; Bhagia, P.; Oh, D-y.Annals of Oncology, 2023, 34(3): 319-320.被引 26
- The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinomaRha, S. Y.; Kawazoe, A.; Bai, Y.; Xu, J.; Lonardi, S.; Metges, J-P.; Yanez Weber, P. E.; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y. V.; Bilici, M.; Chung, H. C.; Shitara, K.; Qin, S.; van Cutsem, E.; Tabernero, J.; Li, K.; Shih, C-S.; Bhagia, P.; Janjigian, Y. Y.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
会议论文
KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1-selected populations
4被引17阅读
